AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 132 min read$ABBV

Abbvie's Crohn's Disease Drug Skyrizi Shows More Positive Results

Abbvie reported positive results from its Phase 3 trial of Skyrizi for Crohn's disease, with 36% of patients achieving endoscopic remission. The study showed higher efficacy in advanced therapy-naive patients. Skyrizi is under regulatory review by the FDA and EMA for subcutaneous induction in adults with Crohn's disease, according to the company.

Original reporting
marketscreener.com
Published Oct 13, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ABBV
Bullish
high confidence
Mentioned
$ABBV
Relevance
8/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$ABBVBullishMed
01

Why it matters

The data could accelerate regulatory submissions and expand the drug's market opportunity.

02

Market read

First report of pivotal trial results; likely to move AbbVie's share price and influence the IBD therapeutic space.

03

What to watch

Regulatory review timelines and potential competition from other IBD therapies could temper upside.

Relevance 8/10Novelty 9/10Timing: today

Background

AbbVie is seeking FDA and EMA approval for Skyrizi in Crohn's disease following earlier ulcerative colitis success.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie reported Phase 3 Skyrizi trial results showing 36% endoscopic remission in Crohn's disease patients.

Expected impact

upward pressure as market prices in the favorable efficacy data

Evidence & confidence

Phase 3 data are material for a biotech; investors typically bid up shares on positive outcomes.

Market effects

Sector

Strengthens the biotech/IBD therapeutic segment and may boost peer valuations.

Regional

U.S. biotech market may see modest gains; European markets less affected.

Global

Adds optimism to global drug development pipelines for inflammatory bowel diseases.

Counterpoint

What could challenge this read

Investors may question durability of remission and await longer-term data before committing.

Key entities

  • Company
    AbbVie

    U.S.-listed biopharma developing Skyrizi.

Read at source← All news

StoryAbbVie reports positive Phase 3 Skyrizi data in Crohn’s disease

Also covered by

2 outlets

Related articles

OCT 13
$ABBVHigh

AbbVie (ABBV) Reports Promising Phase 3 AFFIRM Trial Results for

AbbVie (ABBV) reported positive Phase 3 AFFIRM trial results for Skyrizi in treating Crohn’s disease, showing 35.8% endoscopic remission. The company has a 2.48% dividend yield, 85% payout ratio, and is overvalued by 23.5% per GF Value. ABBV's GF Score is 76/100, with strong profitability but mixed financial strength and momentum. Insiders sold $17.7M shares, while 18 gurus hold ABBV shares, evenly split between additions and trims.

gurufocus.com2 min
OCT 13
$ABBVMedAI 8/10

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

AbbVie presented Phase 3 AFFIRM study results showing subcutaneous SKYRIZI® (risankizumab-rzaa) achieved higher endoscopic remission and ulcer-free endoscopy rates in Crohn's disease patients vs. placebo. The data supports FDA approval for a new induction dosing regimen. SKYRIZI is already approved for other immune-mediated diseases.

news.abbvie.com5 min
OCT 12
$VRTXMedAI 8/10

Biotech’s Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism

Biotech stocks are rebounding due to record pharmaceutical M&A deals, with 37 acquisitions worth at least $1B each in 2026, totaling $216B. Key deals include Vertex (VRTX) acquiring Crinetics (CRNX) for $10B. Institutional investors are bullish, but retail sentiment is low. The Direxion Biotech Bull 3x Shares (LABU) fund has gained 52.5% YTD, despite its index being down last week.

etfdb.com2 min
OCT 12
$ABBVMed

AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026

AbbVie presented 22 abstracts at ACG 2026, highlighting long-term data for SKYRIZI and RINVOQ in treating IBD. Phase 3 AFFIRM trial showed SKYRIZI's efficacy in Crohn's disease, with 74.5% of patients with fistulizing Crohn's disease achieving no draining fistulas after five years. RINVOQ also showed sustained improvements in difficult-to-treat Crohn's disease. ABBV stock closed at $276.47, up 1.49%.

rttnews.com2 min